Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Two-Drug combo targets Hard-to-Treat myeloma in early trial

NCT ID NCT06215118

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times

Summary

This early-stage study is testing whether a combination of two drugs—elranatamab (given as a shot) and iberdomide (taken as a pill)—is safe and tolerable for people with multiple myeloma that has returned or stopped responding to prior treatments. The trial will enroll about 87 participants and has two parts: first to check safety, then to find the right dose. It is not a cure, but if successful, it could provide a new way to control this blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
elranatamab (a drug that helps the immune system attack cancer cells) and iberdomide (a pill that targets cancer cells)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with multiple myeloma that has returned or stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1) study with only 87 participants, so it is primarily testing safety and dosing. The combination may not work well or could cause serious side effects. It is not a cure and will likely require ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

100 people

The number who actually took part.

Started

Feb 2024

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prior diagnosis of multiple myeloma as defined by IMWG criteria * Measurable disease based on IMWG criteria as defined by at least 1 of the following: * Serum M-protein ≥0.5 g/dL by SPEP * Urinary M-protein excretion ≥200 mg/24 hour by UPEP * Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FL ratio (\<0.26 or \>1.65) * Part 1: Received 2-4 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor. * Part 2: Received 1-3 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor. * ECOG performance status 0-1 * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1 Exclusion Criteria: * Plasma cell leukemia, Smoldering multiple myeloma, Waldenström's macroglobulinemia, Amyloidosis, POEMS Syndrome * Impaired cardiovascular function or clinically significant cardiovascular diseases * Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease * Participants with any active, uncontrolled bacterial, fungal, or viral infection * Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ * Previous treatment with: * BCMA-directed or CD3 redirecting therapy * Iberdomide (CC-220) or Mezigdomide * Administration of strong inhibitor or inducer of CYP3A4/5 within 2 weeks prior to dosing and during the study * Administration with an investigational product within 30 days preceding the first dose of study intervention * Participant is unable or unwilling to undergo protocol required thromboembolism prophylaxis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • CIUSSS de l'Est-de-l'Île-de-Montréal

    Montreal, Quebec, H1T 2M4, Canada

  • Calvary Mater Newcastle

    Waratah, New South Wales, 2298, Australia

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Dana-Farber Cancer Institute - Chestnut Hill

    Newton, Massachusetts, 02459, United States

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire, 03756, United States

  • Dr. Everett Chalmers Regional Hospital

    Fredericton, New Brunswick, E3B 5N5, Canada

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308, United States

  • Epworth Freemasons

    East Melbourne, Victoria, 3002, Australia

  • Epworth Hospital

    Richmond, Victoria, 3121, Australia

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Indiana CTSI Clinical Research Center (ICRC)

    Indianapolis, Indiana, 46202, United States

  • Indiana University Health University Hospital

    Indianapolis, Indiana, 46202, United States

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC)

    Indianapolis, Indiana, 46202, United States

  • Liverpool Hospital

    Liverpool, New South Wales, 2170, Australia

  • MSK Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • MSK Bergen

    Montvale, New Jersey, 07645, United States

  • MSK Commack

    Commack, New York, 11725, United States

  • MSK Monmouth

    Middletown, New Jersey, 07748, United States

  • MSK Nassau

    Uniondale, New York, 11553, United States

  • MSK Westchester

    Harrison, New York, 10604, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).

    New York, New York, 10021, United States

  • Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy

    Long Island City, New York, 11101, United States

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York, 10065, United States

  • Methodist Hospital

    Omaha, Nebraska, 68114, United States

  • Oncology Hematology West P.C. dba Nebraska Cancer - Methodist

    Omaha, Nebraska, 68114, United States

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists

    Omaha, Nebraska, 68130, United States

  • Slade Pharmacy

    Richmond, Victoria, 3121, Australia

  • Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

    Coral Gables, Florida, 33146, United States

  • Sylvester Comprehensive Cancer Center Kendall

    Miami, Florida, 33176, United States

  • Sylvester Comprehensive Cancer Center Plantation

    Plantation, Florida, 33324, United States

  • Sylvester Comprehensive Cancer Center- Doral

    Doral, Florida, 33166, United States

  • Townsville University Hospital

    Douglas, Queensland, 4814, Australia

  • University of Maryland

    Baltimore, Maryland, 21201, United States

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts, 01655, United States

  • University of Miami Hospital and Clinics

    Miami, Florida, 33136, United States

  • University of Miami Hospital and Clinics Deerfield Beach

    Deerfield Beach, Florida, 33442, United States

  • University of Washington

    Seattle, Washington, 98195, United States

  • Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.